Adamed's Polish anti-cancer drug to begin clinical trials

One of the firm's latest projects, operating under the working title of Aserin, might result in the launch of a drug for treating lung and bladder cancers. "We now begin clinical testing in Poland and abroad. We intend to carry out the first registration in the USA, but it will not possible earlier than in 2009," said Adamed general director Sławomir Mirek. The company is now waiting for conclusion of the patenting process of the drug. So far Adamed has spent zł.53 million on R&D activities, as part of its strategy until 2010. As a result the firm has managed to push some of the drugs being offered by foreign competitors off the market. (Puls Biznesu, p. 9) M.M.